Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.49 |
| ▸ | RXRB | P28702 | 15/20 | 0.49 |
| ▸ | RXRG | P48443 | 14/20 | 0.49 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 4/20 | 0.42 |
| ▸ | RARG | P13631 | 4/20 | 0.42 |
| ▸ | RARA | P10276 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24750771 | 0.88 | RXRA (0.49) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL23449193 | 0.82 | RXRA (0.48) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL10109610 | 0.80 | OPRD1 (0.37) | RXRARXRBRXRGALDH1A1ALOX15 | |
| SCHEMBL22202402 | 0.77 | RXRA (0.51) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL1614829 | 0.76 | RXRA (0.53) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL25714566 | 0.75 | RXRA (0.39) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL22936149 | 0.74 | RXRA (0.43) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL22938028 | 0.74 | RXRA (0.43) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL2984190 | 0.73 | RXRA (0.42) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL22202395 | 0.73 | RXRA (0.42) | RXRARXRBRXRGCYP26B1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157154-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-18 | — | — | US | disclosed |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | PFAHL MAGNUS | 2006-07-20 | — | — | US | disclosed |
| US-7071218-B2 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | INCYTE SAN DIEGO INCORPORATED (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1456187-A4 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1456187-A1 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003043998-A1 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157154-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LIFR, SOD1, GLRA3 | RXRA 905/4885RXRB 941/4885RXRG 1001/4885 |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, CYP46A1, PNLIP | RXRA 817/4885RXRB 972/4885RXRG 728/4885 |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, PC, PNLIP | RXRA 778/4885RXRB 908/4885RXRG 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.